Clinical Trials
95 trialsTesting the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
National Cancer Institute (NCI)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
National Cancer Institute (NCI)
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
National Cancer Institute (NCI)
A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)
GlaxoSmithKline
Combination Chemotherapy of Paclitaxel and Carboplatin With or Without Anthracycline as Aneo Adjuvant Treatment in Advanced Endometrial Carcinoma
Sohag University
TroFuse-033
Merck Sharp & Dohme LLC
Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer
M.D. Anderson Cancer Center
Fern-EC-01
BioNTech SE
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
AstraZeneca
RAINBO
Leiden University Medical Center
A Study of PHST001 in Advanced Solid Tumors
Pheast Therapeutics
FIERCE
University of Oklahoma
DOVE
Yonsei University
DE-01
AstraZeneca
KEYNOTE-C93
Merck Sharp & Dohme LLC
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
National Cancer Institute (NCI)
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
M.D. Anderson Cancer Center
Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer
Danish Gynecological Cancer Group
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Fate Therapeutics
TroFuse-005
Merck Sharp & Dohme LLC
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
Eisai Inc.
MK-3475-775
Eisai Inc.
PETRA
AstraZeneca
Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Ohio State University Comprehensive Cancer Center
A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer
Memorial Sloan Kettering Cancer Center
LEAP-001
Merck Sharp & Dohme LLC
ASCENT-GYN-01
Gilead Sciences
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
Faeth Therapeutics
DUO-E
AstraZeneca
A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)
GlaxoSmithKline
Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
Washington University School of Medicine
LEAP-001
Merck Sharp & Dohme LLC
KEYVIBE-005
Merck Sharp & Dohme LLC
BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer
Bio-Thera Solutions
A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors
Incyte Corporation
P204
Leap Therapeutics, Inc.
Combination Chemotherapy With Nintedanib / Placebo in Endometrial Cancer
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
RUBY-J
GlaxoSmithKline
Proactive Immune Tolerance Induction in Chemotherapy for Gynecologic Cancer
Seoul National University Hospital
The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach
University of Maryland, Baltimore
KEYNOTE-B21
Merck Sharp & Dohme LLC
AtTEnd
Mario Negri Institute for Pharmacological Research
Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma
Ohio State University Comprehensive Cancer Center
Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer
Ohio State University Comprehensive Cancer Center
A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor
Huabo Biopharm Co., Ltd.
Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer
Hutchmed
MK-3475 Immunotherapy in Endometrial Carcinoma
Washington University School of Medicine
A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors
Deciphera Pharmaceuticals, LLC
QL1706 Combined with Chemotherapy in the Treatment of Recurrent or Metastatic Endometrial Cancer
Peking Union Medical College Hospital